Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2011-02-16 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2010
Interim / Quarterly Report Classification · 1% confidence The document is a 'Year-end Report' for Orexo AB covering the period from January to December 2010. It contains comprehensive financial statements, including income statements, revenue breakdowns, and management commentary on business performance, strategy, and outlook. It is not an announcement of a report, but the report itself, and it provides substantive financial data for a period shorter than a full fiscal year (in the context of the quarterly breakdown) and the full year, fitting the definition of an Interim/Quarterly Report. FY 2010
2011-02-16 English
Earnings Release 2010
Earnings Release Classification · 1% confidence The document title is "Orexo AB (publ.) – bokslutskommuniké januari-december 2010" which translates to "Year-end report communication January-December 2010". The text contains detailed financial statements, including a consolidated income statement ('Koncernens resultaträkning i korthet') covering the full 12 months of 2010 and the fourth quarter, along with management commentary on results, revenue breakdown, and key events for the full year. This structure and content strongly indicate a comprehensive annual financial report, even though the Swedish term 'bokslutskommuniké' often precedes the formal 10-K filing. Given the depth of financial data covering the entire fiscal year, it aligns best with the Annual Report category (10-K), which encompasses the full yearly performance review. FY 2010
2011-02-16 Swedish
Orexo och Invida ingår avtal avseende Abstral™ i Asien och Stillahavsområdet
M&A Activity Classification · 1% confidence The document is a press release dated January 14, 2011, announcing a licensing and distribution agreement between Orexo AB and Invida Group Private Limited regarding the drug Abstral™ in the Asia-Pacific region. The text details the terms of the agreement, quotes executives, and provides background information on the drug and the companies involved. Crucially, the final note states: "Informationen är sådan som Orexo AB (publ) ska offentliggöra enligt lagen om handel med finansiella instrument och/eller lagen om värdepappersmarknaden." (The information is such that Orexo AB (publ) shall disclose pursuant to the Financial Instruments Trading Act and/or the Securities Market Act.) This structure strongly indicates a mandatory regulatory disclosure, often released via a news wire service. Since it is a general announcement of a significant business event (a major partnership) that doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR), the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings). It is not a specific financial report, earnings release, or management discussion.
2011-01-14 Swedish
Orexo and Invida jointly announce agreement for Abstral™ in Asia Pacific
Regulatory Filings Classification · 1% confidence The document is a press release dated January 14, 2011, announcing an exclusive licensing and distribution agreement between Orexo AB and Invida Group Private Limited for the product Abstral™ in the Asia Pacific region. This type of announcement, detailing a strategic business partnership, licensing deal, or commercial agreement, does not fit the specific definitions for financial reports (10-K, IR, ER), regulatory filings (RNS), capital changes (CAP, SHA), or management changes (MANG). It is a general corporate announcement regarding business development. Since there is no specific category for 'Partnership Announcement' or 'Licensing Agreement', and it is not a standard regulatory filing like a 10-K or an earnings release, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous corporate announcements that do not fit elsewhere, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. Given the options, RNS is the best fit for a non-standard, material corporate announcement.
2011-01-14 English
Anders Lundström utsedd till ny VD för Orexo
Board/Management Information Classification · 1% confidence The document is a press release dated January 13, 2011, announcing the appointment of Anders Lundström as the new CEO of Orexo AB. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is short and clearly structured as an official announcement, not a comprehensive financial report (like 10-K or IR). Therefore, the appropriate code is MANG.
2011-01-13 Swedish
Anders Lundström to be the new CEO of Orexo
Board/Management Information Classification · 1% confidence The document is a press release dated January 13, 2011, announcing that Anders Lundström has been appointed as the new CEO of Orexo AB, replacing Torbjörn Bjerke. This content directly relates to changes in senior management personnel. Based on the provided definitions, this falls under 'Board/Management Information' (Code: MANG). The document is not a financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2011-01-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.